Platinum-based chemotherapy, such as cisplatin or carboplatin, is standard treatment for advanced ovarian cancer. However, even in cancers that initially shrink with this therapy, the cancer often comes back. Usually, no treatment is given after the chemotherapy unless the cancer comes back. In this study, researchers want to see if giving patients with BRCA-mutated advanced ovarian cancer the investigational drug olaparib after they finish platinum-based chemotherapy reduces the chance that their cancer will return.
Olaparib kills cancer cells by blocking the PARP protein, thereby preventing the repair of DNA or genetic damage in cancer cells. Prior research has shown that olaparib may have activity against high-grade ovarian cancer. Olaparib is taken orally (by mouth).
Patients in this study will be randomly assigned to one of two groups. Two-thirds of the patients will receive olaparib, and one-third will receive a placebo. Patients will be tested to see if they have BRCA mutations. Cancer cells for these mutations are especially sensitive to olaparib.